1 / 34

Perioperative Myocardial Infarction - Etiology and Prevention

Perioperative Myocardial Infarction - Etiology and Prevention. R3 김상영. PMI. Predictor of short- and long-term morbidity and mortality 예방을 위해 etiology 를 잘 알아야 함 Etiology : 명확하게 밝혀지지 않음 여러요소가 관련됨 계속 논의중인 영역.

Download Presentation

Perioperative Myocardial Infarction - Etiology and Prevention

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Perioperative Myocardial Infarction- Etiology and Prevention R3 김상영

  2. PMI • Predictor of short- and long-term morbidity and mortality • 예방을 위해 etiology를 잘 알아야 함 • Etiology : 명확하게 밝혀지지 않음 여러요소가 관련됨 계속 논의중인 영역

  3. Etiology of PMI

  4. Etiology of PMI Acute Coronary Syndrome • Etiology • 관련인자 : plaque(structurally&functionally), coronary a. stenosis, coronary endothelial lesions, plaque inflammation • Plaque : structural morphology, cellular composition, biological activity : exogenous factors (mechanical stress, vasomotor tone, infection, blood viscosity, coagulability) : systemic or multi-focal arterial inflammation

  5. Etiology of PMI Acute Coronary Syndrome • Pathophysiology • Plaque progression • abrupt, unpreditable 종종 thrombosis발생에 관여 • Risk factors & triggers : physical activity, mental stress, environmental temperature, smoking, infection, hydration, arterial pr.

  6. Etiology of PMI Acute Coronary Syndrome • Plaque rupture • causes - mechanical stress, coronary vasospasm, widespread acute inflammatory endothelial activation, or the chronic inflammatory component of atherosclerosis • size of thrombus • strenuous physical activity & emotional stress ⇒ sympathetic tone↑⇒ 응고경향↑ ⇒ torombosis↑ 수술중 환경과 비슷!!

  7. Etiology of PMI Acute Coronary Syndrome • angiographically fairly small coronary lesion ⇒ progress acutely to severe stenosis or total occlusion • MI • If coronary blood flow is interrupted for longer than 30 min, a MI may result • 시간지날수록 size 커짐

  8. Etiology of PMI Perioperative MI • Etiology • 여러 요소들이 복합적으로 작용한다는 개념 (CAG, EKG, oxygen supply/demand mismatch, plaque rupture) • Most(>80%) PMIs occur early after surgery • Asymptomatic, non-Q-wave type • ST-seg depression(duration이 중요) • Serum troponin concentration • HR의 증가가 동반되기도 • Prolonged stress-induced myocardial ischemia → primary cause of PMI!!

  9. Etiology of PMI Perioperative MI • 수술끝날무렵, 깨울때 잘 생김 (HR↑, a.pr. ↑, sympathetic tone↑, procoagulant activity↑) • 기존에 CAD있으면 plaque에 의하지 않아도 coronary a. thrombosis유발가능 • Plaque disruption • Thrombosis와 thrombolysis간에 균형, 충분한 flow condition

  10. Etiology of PMI Perioperative MI • Diagnosis • MI Dx criteria (WHO) • i) typical ischemic chest pain • ii) increased serum concentration of creatine kinase (CK)-MB isoenzyme • iii) typical electrocardiographic findings, including development of pathological Q-waves

  11. Etiology of PMI Perioperative MI • Revised definition of MI(by the ESC & ACC) • (1) typical rise and gradual fall in cardiac troponin concentrations or more rapid rise and fall of CK-MB concentration in combination with at least one of the following • (a) typical ischemic symptoms • (b) development of pathological Q-waves in the ECG • (c) ECG changes indicative of myocardial ischemia • (d) coronary a. intervention • (2) pathological findings of an acute MI

  12. Etiology of PMI Perioperative MI • High specificity of cardiac troponin • MI & Troponin concentration • cTnI > 1.5 ng ml & cTnT > 0.1 ng ml • Cardiac troponin이 CK-MB보다 더 적합 • 전통적 정의 ⇒ underestimate troponin을 이용한 정의 ⇒ overestimate • Long term survival rate에 영향 • 소량의 증가도 유의한 결과로 받아들여야

  13. Prevention of Perioperative MI

  14. Prevention of perioperative MI Preoperative Coronary Revascularization 지지자측 : improve perioperative and long- term outcome 반대자측 : 시술자체의 risk, 시술후의 수술 시 기에 따른 예후

  15. Prevention of perioperative MI Preoperative Coronary Revascularization • Preoperative coronary angiography • Positive DTS pts.에서 시행 • Perioperative cardiac outcome향상 • Cardiac evaluation중에 MI 2명, death 3명 • 통계적으로 유의한 결과 없었음 • 결론 : 유익한 추가정보를 주거나 이익을 준다고 생각되지 않음

  16. Prevention of perioperative MI Preoperative Coronary Revascularization • Percutaneous transluminal coronary angioplasty (PTCA) • 자료의 크기와 design이 적절하지 않음 • 후향성 연구에서는 효과가 있다고 나옴 • Angina pectoris & congestive heart failure↓ but not in non-fatal PMI & mortality • 시술 90일 후에는 유의한 유익 없음

  17. Prevention of perioperative MI Preoperative Coronary Revascularization • Coronary stenting • Fatal cardiac event의 원인 : stent thrombosis • 시술후 6주 이내에 수술한 그룹에서 발생 • 7~9주 후에 수술한 그룹에서는 없었다

  18. Prevention of perioperative MI Preoperative Coronary Revascularization • Preoperative surgical coronary revascularization • 수술전에 CABG시행한 그룹이 PMI와 mortality에서 향상된 값을 보임 • Advanced angina & multi-vessel CAD에서 특히 뚜렷 • Minor op.시에는 차이점 없었다 • CABG시행 후 1달이내에 수술한 그룹에서 MI↑, mortality↑ • 6개월 뒤에 수술 권장

  19. Prevention of perioperative MI Preoperative Coronary Revascularization • Risk calculation in preoperative coronary revascularization • 시술 자체의 risk를 배제했던 결과들 • 모두 감안하면 오히려 총 risk가 높아질 수 있다 • 수술만 놓고 보면 수술 단독군이 risk가 적다 • Long-term outcome까지 고려해야 함 (추후에 시술을 받을 가능성이 얼마인지)

  20. Prevention of perioperative MI Preoperative Coronary Revascularization • Recommendations for preoperative coronary angiography • 수술예정이 아닌 환자와 비슷한 Ix을 적용 • Ix • (i) evidence for high risk of adverse outcome based on non-invasive test results • (ii) angina pectoris unresponsive to adequate medical therapy • (iii) unstable angina, particularly when facing intermediate or high risk non-cardiac surgery • (iv) equivocal non-invasive test results in patients at high clinical risk undergoing high risk surgery

  21. Prevention of perioperative MI Preoperative Coronary Revascularization • Recommendation for preoperative coronary intervention • 수술과 관계없는 환자와 비슷하게 적용 • PTCA • Balloon plasty한 자리가 다 아문뒤에 수술하는 것이 좋다 (적어도 일주일 뒤)

  22. Prevention of perioperative MI Preoperative Coronary Revascularization • Coronary stenting • Dual antiplatelet medication (thienopyridine & aspirin) • Re-endothelialization (대략 8주) • Re-stenosis (대략 6-8주) • 수술연기 : 절대적으로 2주 4-6주가 적당 • Drug-eluting stent : stent stenosis가능성↑, antipletelet 복용기간↑ 수술 몇 달 연기하는게 낫다 • 2달이내 수술이 필요한 경우 • Dual antipletelet therapy를 surgeon이 인정하면 drug-eluting stent도 가능

  23. Prevention of perioperative MI Preoperative Coronary Revascularization • 2달이내 수술이 필요한 경우 • Dual antipletelet therapy를 surgeon이 인정하면 drug-eluting stent도 가능 • 인정 안하면 heparin-or phosphorylcholine-coated stent이용이 효과적 • PTCA without stent placement

  24. Prevention of perioperative MI Preoperative Coronary Revascularization • Recommendation for preoperative surgical coronary revascularization • 역시 수술안하는 사람과 유사한 Ix적용 • Ix • (i) acceptable coronary revascularization risk and suitable viable myocardium with left main stenosis • (ii) three-vessel CAD in conjunction with left ventricular dysfunction • (iii) two-vessel disease involving severe proximal left ant. Descending a. obx. • (iv) intractable coronary ischemia despite maximal medical therapy • 적어됴 4-6주 뒤에 수술. 가능하면 6달 이후가 바람직

  25. Pharmacological treatment

  26. Pharmacological treatment Beta-blocker • Rationale for the use of perioperative β-blocker therapy • 장점들 : anti-arrhythmic, anti-inflammatory, altered gene expression and receptor activity, protection against apoptosis • 효과들 : reduces post-myocardial infarction mortality reducing myocardial oxygen consumption • Activation of hypothalamus-pituitary-adrenal axis : 수술후 적어도 1주일

  27. Pharmacological treatment Beta-blocker • Atenolol, bisoprolol • 퇴원후 2년내 유병률 비교 • Risk reduction있었다 • 실험에 대해 여러 비판도 존재 • Thoracic epidural, α2-adrenergic agonists과의 병용치료 여부에 대해 검증 미비 (bradycardia, hypotention)

  28. Pharmacological treatment Beta-blocker • Thoracic epidural, α2-adrenergic agonists과의 병용치료 여부에 대해 검증 미비 (bradycardia, hypotention) • Β-blocker약제는 뭘 선택해도 무방하다 • 시작시기는 수술 1주전부터. 늦어도 premedi시 • 수술중 HR을 50-60bpm으로 조절 술후에도 80bpm을 넘지 않도록 • 술후 적어도 1주, 보통 한달 복용 • 갑자기 투여 중지하면 withdrawal Sx. 서서히 감량해야 • 집중관찰하여 terget rate에서 조절해야 효과가 있었다

  29. Pharmacological treatment Beta-blocker • ACC/AHA Class I guidelines • (i) the need for β-blockers in the recent past to control symptoms of angina • (ii) patients with symptomatic arrhythmias or hypertension • (iii) patients at high risk for a perioperative cardiac event based on the finding of myocardial ischemia on perioperative testing

  30. Pharmacological treatment Beta-blocker • Β-blocker의 CIx • Symptomatic bradycardia(<50-60bpm) • Symptomatic hypotension(<90-100mmHg) • Severe heart failure requiring i.v. diuretics or inotropes • Cardiogenic shock • Asthma or reactive airway disease requiring bronchodilator and/or steroids • 2 or 3 degree AV block

  31. Pharmacological treatment Alpha-2 adrenoceptor agonists • Clonidine • 0.2mg orally • Reduced perioperative myocardial ischemia and improved 30-day and 2-yr mortality • But had no effect on PMI • Inhibit central sympathetic discharge, reduce peripheral norepinephrine release, and dilate post-stenotic coronary vessels

  32. Pharmacological treatment Aspirin • Improved outcome following CAB surgery • Eliminates the diurnal variation in plaque rupture • Anti-inflammatory effect

  33. Pharmacological treatment Statins • Lipid-lowering therapy • Plaque size↓ • Pleiotropic effects • Reversal of endothelial dysfunction • Modulation of macrophage activation • Immunological effects • Anti-inflammatory, antithrombotic and antiproliferative actions

  34. Conclusions • PMI의 etiology는 다방면성 • High risk group환자의 경우 long-term outcome을 고려하여 술전 시술이 더 유익한지를 판단해야 함 • 술전, 술중, 술후 약제를 이용한 관리 • 집중적으로 모니터링해야 함

More Related